Abionyx Pharma SA

Abionyx Pharma SA has a market price of 3.71 EUR and a market capitalization of 130,937,215.5 EUR, with a price-to-book ratio of 29.02 and a price-to-tangible-book ratio of 29.02. The company's enterprise value to EBITDA is -24.33, and its enterprise value to revenue is 33.16. The company's return on equity is -1.2301, and its return on assets is -0.4232. The company's capital structure is characterized by a debt-to-equity ratio of 0.84 and a current ratio of 1.06. The company has total assets of 13,115,000 EUR and total liabilities of 8,603,000 EUR, with a total equity of 4,512,000 EUR. The company's long-term debt is 3,805,000 EUR. In terms of profitability, the company reported a revenue of 4,063,000 EUR and a gross profit of 534,000 EUR. However, the company has an operating income of -5,538,000 EUR and a net income of -5,550,000 EUR. The company's operating cash flow is -2,933,000 EUR, and its free cash flow is -5,302,000 EUR. The company's segments and geographic exposure are not explicitly detailed in the provided data. However, the company is present in Labege in Midi-Pyrenees in France and in Ann Arbor in Michigan in the United States. It also operates through LYPRO Biosciences Inc. The company's growth trajectory is not clearly defined in the provided data. The company has a capital expenditure of -242,000 EUR and a negative operating cash flow. The company's liquidity is rated as medium, and its dilution is rated as low. Recent events and filings indicate that the company has a mean price target of 11.00 EUR, with a median, high, and low price target of 11.00 EUR. The mean recommendation is 1.50, with one strong-buy count and one buy count.